Processing session initiation protocol messages

Details for Australian Patent Application No. 2005201046 (hide)

Owner Microsoft Corporation

Inventors Narayanan, Sankaran; Eydelman, Vadim; Buch, Jeremy Thomas; Su, Jinyan

Agent Davies Collison Cave

Pub. Number AU-B-2005201046

Priority 10815232 31.03.04 US

Filing date 9 March 2005

Wipo publication date 20 October 2005

Acceptance publication date 26 November 2009

International Classifications

H04L 9/36 (2006.01) Arrangements for secret or secure communication - with means for detecting characters not meant for transmission

H04L 9/32 (2006.01) Arrangements for secret or secure communication - including means for verifying the identity or authority of a user of the system

H04L 29/06 (2006.01) Arrangements, apparatus, circuits or systems, not covered by a single one of groups - characterised by a protocol

H04L 29/08 (2006.01) Arrangements, apparatus, circuits or systems, not covered by a single one of groups - Transmission control procedure, e.g. data link level control procedure

Event Publications

24 March 2005 Complete Application Filed

  Priority application(s): 10815232 31.03.04 US

20 October 2005 Application Open to Public Inspection

  Published as AU-B-2005201046

2 July 2009 Amendment Made

  The nature of the amendment is: Amend the invention title to read Processing session initiation protocol messages

26 November 2009 Application Accepted

  Published as AU-B-2005201046

25 March 2010 Standard Patent Sealed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2005201047-Dental impression material kneading device

2005201045-Combination therapy of angiotensin converting enzyme inhibitor and epoxysteroidal aldosterone antagonist for treatment of cardiovascular disease